According to Zhitong Finance App, Hualan Biotech (002007.SZ) released its report for the third quarter of 2026. The company achieved operating income of 2,582 billion yuan in the first three quarters, a year-on-year decrease of 23.58%; net profit attributable to shareholders of listed companies was 431 million yuan, a year-on-year decrease of 45.11%; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 384 million yuan, a year-on-year decrease of 48.28%; basic earnings per share were 0.2359 yuan.
In the first three quarters, the company's net profit attributable to shareholders of listed companies fell 45.11% year on year, and net profit attributable to shareholders of listed companies decreased by 48.28% year on year. The main reason is that, according to the “Notice of the Ministry of Finance and the State Administration of Taxation on Matters Relating to Preferential Value-added Tax Policies after the Implementation of the Value-added Tax Law” No. 10 of 2026, blood products and vaccine products will no longer be included in the scope of simple levy of 3% VAT (with the exception of varieties included in the rare disease drug list), and the general tax rate of 13% will be uniformly implemented The sharp increase has further increased the cost pressure on the industry, and profit margins have been significantly compressed; second, on the demand side and price, the continuous deepening of policies such as procurement expansion, DRG/DIP payment method reform, medical insurance fee control, and drug priority monitoring and rational drug use, pharmaceutical industry compliance, etc., led to a marked contraction in clinical prescriptions, a decline in terminal demand, overall industry sales pressure, and price declines; Third: According to the “2026-2027 Northern Hemisphere Influenza Season Recommended Influenza Virus Vaccine Components” issued by the World Health Organization The vaccine component no longer contains the type B Yamagata influenza virus. It is recommended to use the trivalent influenza vaccine component. According to the adjustment of relevant vaccine components, the main product of the Hualan vaccine this influenza season was changed from the quadrivalent influenza vaccine to the trivalent influenza vaccine, and the terminal price was adjusted accordingly. Furthermore, the Hualan vaccine responded positively to the national influenza prevention and control deployment and was deeply involved in the free influenza vaccination program for “one old, one young” key population in rural areas. The relevant vaccines were supplied at preferential policy prices, which combined led to a year-on-year decline in operating income and a corresponding decline in net profit.